



Rinske Boersma

Kontakt

Rinske Boersma

Publikationen (2)

Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkuppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. *Blood Cancer J* 2023; 13:93.

Sonneveld P, von dem Borne P, Durian M, Hájek R, Boersma R, Wu K, Morelli A, Aquino S, Ludwig H, Bos G, Levin M, Benevolo G, Pascarella A, Troia R, Caravita di Toritto T, Zander T, Boccadoro M, Spencer A, Carvalho S, Palmas A, Cafro A, Mandigers C, Minnema M, van Marwijk Kooy M, Mellqvist U, Gimsing P, Waage A, Specchia G, Driessen C, Broijl A, Andersen N, Patriarca F, Palumbo G, Zamagni E, van der Velden V, Oliva S, Zweegman S, van der Holt B, Dozza L, Dimopoulos M, Petrucci M, Pantani L, Beksac M, Gay F, Montefusco V, Galli M, Liberati A, Zambello R, Vincelli I, Offidani M, Ballanti S, Croockewit A, Grasso M, Ypma P, Pour L, Belotti A, Hansson M, Gamberi B, Maisnar V, Cavo M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. *Lancet Haematol* 2020; 7:e456-e468.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch